Lung India

EDITORIAL
Year
: 2019  |  Volume : 36  |  Issue : 1  |  Page : 1--2

In tuberculosis, “one size does not fit all”


Salil Bhargava1, Monika Jain2, Manoj Jain3,  
1 Department of Pulmonary Medicine, MGM Medical College, Indore, Madhya Pradesh, India
2 Rice University, Houston, Texas, USA
3 Adjunct Faculty, Rollins School of Public Health Emory University, Atlanta, Georgia

Correspondence Address:
Prof. Salil Bhargava
Department of Pulmonary Medicine, MGM Medical College, Indore, Madhya Pradesh
India




How to cite this article:
Bhargava S, Jain M, Jain M. In tuberculosis, “one size does not fit all”.Lung India 2019;36:1-2


How to cite this URL:
Bhargava S, Jain M, Jain M. In tuberculosis, “one size does not fit all”. Lung India [serial online] 2019 [cited 2019 Mar 25 ];36:1-2
Available from: http://www.lungindia.com/text.asp?2019/36/1/1/249176


Full Text



India has set itself an ambitious goal of being TB-Free by 2025, as against the same goal of WHO by 2030. If India is to become tuberculosis (TB) free by 2025, or even within our lifetimes, unprecedented effort by the government program (Revised National Tuberculosis Control Program), the private sector and social service sector shall be required. To become TB free, we must achieve >15% (not the present 1.5%) annual decline in TB incidence.[1]

While becoming TB free seems daunting, many have begun taking small steps toward this goal.[2] The current issue of Lung India carries two related articles that address active case finding (ACF) of TB cases and prognosis of drug resistant extrapulmonary-TB.[3],[4] One theme evident from both papers is that “one size (either the diagnostic search for TB patients or the prognosis of EP patients) does not fit all the cases of TB.”

In their article, Mani and the Pondicherry team conducted ACF for TB patients, enlisting medical students to use the Epicollect Open Access mobile application for 2252 homes. They found 55 presumptive cases of TB, of which 51 (93%) underwent investigation and two new cases were diagnosed.

ACF is a pillar in the strategy for TB elimination, by preventing the transmission of new infections and early detection of existing ones.[5] High-risk populations living in slums, poor villages, or tribal areas require ACF. In India, as many as 20% of the population or as many as 260 million people may need TB screening. This monumental task cannot be done by the present government infrastructure alone or by medical students. In fact, one of the reasons for not having a robust ACF program, similar to the Directly Observed Therapy, Short-course program (DOTS), is the lack of human workforce funded and trained for ACF.

While Mani et al.'s article provides one solution – medical students – to successfully conduct ACF, their numbers are small. However, their success can be extrapolated and scaled up using other health allied students from nursing or pharmacy schools and Bachelors in Science students, all of whom could be part of the campaign to end TB.

Mani et al.'s paper underscores a number of key points for ACF in India:

We urgently need unique and diverse community-based models with students, social service organizations, and nonprofit organizationsWe also need ACF models that will use government employees such as anganwadi and accredited social health activist (ASHA) workers. Some or all will be essential to effectively reach the high-risk TB populationThe use of an open-source mobile application shows the success of innovation and technology to leapfrog in community healthHuman resource is the single most important rate-limiting step in adequate and comprehensive ACF programThe use of X-rays needs to be prioritized in new ACF algorithms.

Currently, for many regions in India, a comprehensive ACF strategy is not being implemented though it may be on present on paper. Who should do ACF? Who should be screened? Should ACF be performed using the traditional paper based questionnaires or the more advanced and user friendly digital platforms. How much trainings are necessary? How should the suspected cases by managed? Operational research is required to answer these questions that seem to be critical to the End-TB strategy for India in the face of scant available data.[6]

Of equal importance is to think as to how can an ACF model be replicated, sustained, and scaled up with each new model tweaked for the population it is serving. We will only know what will work for a population by doing a small pilot plan-do-study-act quality improvement cycle with a given model and then scale up as we are successful, simultaneously ironing out the impediments that we face.

The final lesson Mani and team's article teaches us is that all ACF approaches are not the same. They vary with the population being surveyed, the surveyors who are conducting the survey, and the resources, such as X-ray or cartridge based nucleic acid amplification test (CBNAAT), which may be available.

Just as the approach for ACF is not the same for all populations, the prognosis of multidrug-resistant TB (MDR-TB) is not the same for all patients. While the cure rate for MDR-TB is at 52%, the paper by Desai and Joshi[3] showed us that this is not true for all MDR-TB cases. Of the 1743 drug-resistant cases in Mumbai from TN Medical College and BYL Nair Hospital, 4.4% (76) were EP cases with half of them being from the lymph nodes. Overall Extrapulmonary cases E cases had a cure rate of 82%.

The important paper addressing drug resistant extrapulmonary cases underscores several key points about MDR-TB.

We must not resign to a high rate of failure in every case of MDR-TBWe need to consider trials for shorter regimens with EPTBThe body weight of EPTB and drug-resistant EPTB is higher and so patients' dosing and drug regimen and adverse events may vary.

As the title of the Desai and Joshi paper suggests, there is hope with MDR. When we encounter a case of MDR, we need not be in despair and be discouraged by thinking only half will be cured; rather, in the case of EP-MDR, patients experience over 80% cure rates.

With variation in prognosis and variations in ACF outcomes, the work of the clinician as well as the public health officer is more difficult. It requires depth of knowledge, a study of the literature, and application of knowledge and experience to a given situation. In the end, this makes TB care even more challenging and the goal of TB elimination by 2025 or within our lifetimes even more daunting.

References

1Prasad R, Gupta N, Banka A 2025 too short time to eliminate tuberculosis from India. Lung India 2017;34:409-10.
2Prasad BM, Satyanarayana S, Chadha SS, Das A, Thapa B, Mohanty S, et al. Experience of active tuberculosis case finding in nearly 5 million households in India. Public Health Action 2016;6:15-8.
3Mani M, Riyaz M, Shaheena M, Vaithiyalingam S, Anand V, Selvaraj K, et al. Is it feasible to carry out active case finding for tuberculosis in community-based settings? Lung India 2019;36:28-31.
4Desai U, Joshi JM. Extrapulmonary drug-resistant tuberculosis at a drug-resistant tuberculosis center, Mumbai: Our experience – Hope in the midst of despair! Lung India 2019;36:3-7.
5Yuen CM, Amanullah F, Dharmadhikari A, Nardell EA, Seddon JA, Vasilyeva I, et al. Turning off the tap: Stopping tuberculosis transmission through active case-finding and prompt effective treatment. Lancet 2015;386:2334-43.
6World Health Organization. Systematic screening for active tuberculosis Principles and recommendations. World Health Organization; 2013.